ProShare Advisors
KRON

ProShare Advisors’s Kronos Bio KRON Stock Holding History

ProShare Advisors’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,137
Closed -$94K – 1967
2022
Q1 		$94K Sell
13,137
-3,282
-20% -$28K ﹤0.01% 2045
2021
Q4 		$223K Buy
+16,419
New +$257K ﹤0.01% 1964
2021
Q3 		– Sell
-10,070
Closed -$241K – 2137
2021
Q2 		$241K Buy
+10,070
New +$255K ﹤0.01% 2032

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

ProShare Advisors's KRON Position: Q2 2022 in Review

ProShare Advisors sold out of Kronos Bio (KRON) in Q2 2022, closing a stake of 13,137 shares — an estimated $94K sold.

ProShare Advisors first reported a position in KRON in Q2 2021 and held it in 3 quarters. The position peaked at $241K in Q2 2021. 93 funds tracked by Wall St. Rank hold KRON as of Q2 2022.

  • ProShare Advisors reported no remaining Kronos Bio position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 13,137 Kronos Bio shares in Q2 2022, an estimated $94K.
  • ProShare Advisors first reported a position in Kronos Bio in Q2 2021 and held it in 3 quarters.
  • ProShare Advisors's Kronos Bio position peaked at $241K in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.